Format

Send to

Choose Destination
J Psychopharmacol. 2015 Sep;29(9):943-60. doi: 10.1177/0269881115596155. Epub 2015 Aug 5.

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.

Author information

1
Centre for Neuropsychopharmacology, Imperial College London, London, UK.
2
Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
3
Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
4
Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK.
5
Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
6
Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
7
Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK 5 Boroughs Partnership NHS Foundation Trust, Warrington, UK.
8
Centre for Neuropsychopharmacology, Imperial College London, London, UK Clinical Research Unit, GlaxoSmithKline, Cambridge, UK.
9
Centre for Neuropsychopharmacology, Imperial College London, London, UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK.
10
Imanova Ltd, London, UK.
11
Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychology, University of Cambridge, Cambridge, UK.
12
Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, UK.
13
Centre for Neuropsychopharmacology, Imperial College London, London, UK d.nutt@imperial.ac.uk.

Abstract

Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.

KEYWORDS:

Addiction; dopamine D3 receptor; functional magnetic resonance imaging; neurokinin 1 receptor; µ-opioid receptor

PMID:
26246443
DOI:
10.1177/0269881115596155
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center